Analysts at Royal Bank Of Canada began coverage on shares of Prothena Corporation PLC (NASDAQ:PRTA) in a report issued on Thursday, The Fly reports. The firm set an “outperform” rating on the biotechnology company’s stock.

Several other analysts have also recently issued reports on PRTA. BTIG Research initiated coverage on shares of Prothena Corporation PLC in a research note on Friday, May 19th. They issued a “buy” rating and a $80.00 target price on the stock. ValuEngine cut shares of Prothena Corporation PLC from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 27th. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and issued a $70.00 target price on shares of Prothena Corporation PLC in a research note on Thursday, July 6th. Jefferies Group LLC initiated coverage on shares of Prothena Corporation PLC in a research note on Monday, July 10th. They issued a “buy” rating and a $100.00 target price on the stock. Finally, BidaskClub upgraded shares of Prothena Corporation PLC from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, July 19th. One investment analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $77.58.

Shares of Prothena Corporation PLC (PRTA) traded up 1.67% on Thursday, reaching $62.74. 135,571 shares of the company were exchanged. The stock’s market capitalization is $2.40 billion. Prothena Corporation PLC has a 12-month low of $40.58 and a 12-month high of $69.53. The firm has a 50 day moving average price of $59.39 and a 200-day moving average price of $56.18.

Prothena Corporation PLC (NASDAQ:PRTA) last posted its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.89) by $0.43. Prothena Corporation PLC had a negative net margin of 527.56% and a negative return on equity of 33.20%. The business had revenue of $26.81 million for the quarter, compared to analysts’ expectations of $16.08 million. During the same period in the prior year, the company posted ($1.18) EPS. The business’s revenue for the quarter was up 7951.1% compared to the same quarter last year. On average, analysts predict that Prothena Corporation PLC will post ($4.52) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This story was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another site, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/09/14/prothena-corporation-plc-prta-coverage-initiated-by-analysts-at-royal-bank-of-canada.html.

In other news, insider Karin L. Walker sold 5,000 shares of the stock in a transaction on Monday, July 17th. The shares were sold at an average price of $64.89, for a total value of $324,450.00. Following the transaction, the insider now owns 5,000 shares of the company’s stock, valued at approximately $324,450. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Dennis J. Selkoe sold 3,500 shares of the stock in a transaction on Friday, July 7th. The stock was sold at an average price of $58.11, for a total transaction of $203,385.00. Following the completion of the transaction, the director now directly owns 6,345 shares in the company, valued at approximately $368,707.95. The disclosure for this sale can be found here. 3.10% of the stock is owned by corporate insiders.

Several hedge funds have recently added to or reduced their stakes in the stock. Woodford Investment Management Ltd grew its holdings in shares of Prothena Corporation PLC by 2.6% during the 2nd quarter. Woodford Investment Management Ltd now owns 11,400,424 shares of the biotechnology company’s stock valued at $616,991,000 after purchasing an additional 294,213 shares during the last quarter. FMR LLC grew its holdings in shares of Prothena Corporation PLC by 0.7% during the 2nd quarter. FMR LLC now owns 5,699,234 shares of the biotechnology company’s stock valued at $308,443,000 after purchasing an additional 39,926 shares during the last quarter. Wellington Management Group LLP grew its holdings in shares of Prothena Corporation PLC by 4.6% during the 1st quarter. Wellington Management Group LLP now owns 3,158,012 shares of the biotechnology company’s stock valued at $176,185,000 after purchasing an additional 138,979 shares during the last quarter. BlackRock Inc. grew its holdings in shares of Prothena Corporation PLC by 7.8% during the 2nd quarter. BlackRock Inc. now owns 2,947,512 shares of the biotechnology company’s stock valued at $159,519,000 after purchasing an additional 213,578 shares during the last quarter. Finally, State Street Corp grew its holdings in shares of Prothena Corporation PLC by 10.6% during the 2nd quarter. State Street Corp now owns 1,181,365 shares of the biotechnology company’s stock valued at $63,932,000 after purchasing an additional 113,193 shares during the last quarter.

Prothena Corporation PLC Company Profile

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

The Fly

Analyst Recommendations for Prothena Corporation PLC (NASDAQ:PRTA)

Receive News & Ratings for Prothena Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Corporation PLC and related companies with MarketBeat.com's FREE daily email newsletter.